EU Authorized Representative for Medical Devices and IVDs in Europe

For manufacturers based outside the European Union, bringing medical devices or in vitro diagnostic devices into the European market involves more than product quality, technical documentation and regulatory preparation. Before any device is introduced to the European market, the manufacturer must appoint an EU Authorized Representative based within the European Union and formally recognised as the manufacturer’s authorised representative. This function is critical under the Medical Device Regulation and the In Vitro Diagnostic Medical Device Regulation as regulators require a responsible local entity to manage communication, supply documentation and assist with compliance obligations when needed. An eu-authorized-representative is not simply a name on a label. They serve as the legal presence of a non-EU manufacturer and play a vital role in ensuring market access, regulatory trust and ongoing post-market accountability.

 

 

Why an EU Authorized Representative Is Required

European medical device rules are designed to protect patients, healthcare professionals and users by ensuring that every product placed on the market has a clear chain of responsibility. If a manufacturer operates outside the European Union, regulators cannot always interact with them as easily as they would with a locally established company. This is exactly where the EU Authorized Representative becomes essential. The representative offers a formal European presence and acts as the official contact for Competent Authorities, Notified Bodies and other regulatory parties.

Without appointing an authorised representative, a non-EU manufacturer cannot legally place medical devices or IVDs on the European market. This requirement applies across a broad spectrum of products, from low-risk devices to advanced diagnostic technologies. This obligation applies before market entry, meaning the representative must be selected early in the compliance journey rather than as a last administrative step. For companies preparing for European distribution, selecting the right EU Authorized Representative for Medical Devices and IVDs can significantly influence registration readiness, document management and long-term regulatory stability.

 

 

The Written Mandate Between Manufacturer and Representative

The connection between the manufacturer and the EU Authorized Representative must be formalised through a written mandate. This mandate defines the tasks the representative is authorised to perform and confirms the obligations both parties must follow. It is a critical compliance record as it defines the scope of representation, responsibilities, communication roles and the actions required if compliance issues occur.

An unclear or weakly drafted mandate can cause uncertainty at critical moments, particularly during authority requests, inspections, complaint handling or corrective actions. A strong mandate should clearly describe how documents will be made available, how regulatory communication will be handled, how incident information will be shared and what happens if the manufacturer does not meet its duties. Therefore, the mandate must be carefully drafted and reviewed before registration or market entry begins.

 

 

Label and Packaging Requirements

The name and address of the EU Authorized Representative must be displayed on the device label, packaging or associated product information in accordance with applicable regulations. This enables authorities, distributors, healthcare professionals and users to identify the local representative connected to the device. It also reinforces the representative’s role as the official European presence for a manufacturer located outside the European Union.

Labelling accuracy matters because incorrect or missing representative information can create compliance concerns and may delay market access. Manufacturers should ensure that their artwork, instructions, declarations and registration information are aligned before products are released. If the representative changes, labelling and registration details may also need to be updated in a controlled and timely manner.

 

 

Documentation Review and Availability

One of the important duties of an EU Authorized Representative for Medical Devices and IVDs is to verify that key compliance documents are available and properly prepared. This includes checking that the EU Declaration of Conformity exists, that technical documentation has been compiled and that the manufacturer has followed an appropriate conformity assessment route for the device type and risk class.

The representative may also be required to retain or access copies of technical files, declarations and Notified Body certificates. These documents must be available for inspection by Competent Authorities for the required retention period after the last device has been placed on the market. This places document control at the core of the manufacturer–representative relationship. Manufacturers should maintain updated records and ensure that the representative can respond quickly if regulators request information.

 

 

Communication With Competent Authorities and Notified Bodies

The EU Authorized Representative serves as the formal communication link between the non-EU manufacturer and European regulatory authorities. If a Competent Authority requests information, samples, technical documentation or clarification, the representative is expected to support the response process. The representative may also communicate with Notified Bodies when required, especially where certificates, conformity assessment or corrective actions are involved.

This communication role requires more than forwarding messages. A dependable representative should understand regulatory requirements, maintain accurate records and ensure responses are delivered within required timelines. Late or incomplete replies can lead to serious consequences, including market limitations or additional regulatory scrutiny. Therefore, manufacturers should partner with a representative who has strong regulatory expertise and well-defined internal systems.

 

 

Post-Market Surveillance and Incident Support

Compliance for medical devices does not stop once the product reaches the market. Once a device is in use, manufacturers must continue monitoring performance, complaints, incidents and safety signals. The EU Authorized Representative has a role in supporting this post-market responsibility by passing complaints and incident information to the manufacturer without delay.

This is especially important when information comes from clinicians, patients, users, distributors or authorities. Timely reporting allows the manufacturer to determine whether investigation, reporting, field safety actions or corrective measures are required. An effective representative recognises that post-market surveillance goes beyond documentation. It is part of patient safety, product improvement and ongoing regulatory trust.

 

 

Registration Responsibilities and EUDAMED

Within European regulatory frameworks, manufacturer and representative details must be registered as necessary. The EU Authorized Representative may support the registration of both the manufacturer and representative information in EUDAMED. Accurate registration enables authorities to identify responsible entities, review device data and maintain market supervision.

Manufacturers should gather complete company information, device details, certificates and declarations before starting registration. Any inconsistency between labels, declarations, technical files and registration records can create delays or compliance questions. The representative’s role helps ensure all required information is aligned and accessible when required.

 

 

When the Representative Must Take Action

An EU Authorized Representative also carries responsibilities if the manufacturer does not fulfil regulatory requirements. If serious non-compliance occurs and the manufacturer does not correct the issue, the representative may eu-authorized-representative need to end the mandate and inform relevant authorities and the Notified Body where applicable. This responsibility shows why the role is more than administrative.

The representative has legal accountability and cannot ignore major compliance failures. Manufacturers should therefore treat the representative as a regulatory partner rather than a passive service provider. Open communication, timely document updates and clear responsibility sharing help prevent misunderstandings and reduce risk during the product life cycle.

 

 

Choosing the Right EU Authorized Representative

Choosing an EU Authorized Representative requires careful consideration. Manufacturers should evaluate regulatory expertise, experience in medical devices and IVDs, document management capabilities, clear response processes and strong knowledge of European regulations. The representative should effectively handle authority communication, maintain records and guide the manufacturer on practical compliance matters.

Cost should not be the only factor. An ineffective representative may lead to delays, communication gaps and increased risk, whereas a strong representative can support confidence during market entry and beyond. The right choice gives non-EU manufacturers a dependable European presence and supports smoother regulatory management.

 

 

Conclusion

An EU Authorized Representative is a mandatory requirement for non-EU manufacturers aiming to introduce medical devices or IVDs into the European market. The role covers legal representation, document availability, regulatory communication, complaint management, registration assistance and intervention in cases of serious non-compliance. Under the Medical Device Regulation and In Vitro Diagnostic Medical Device Regulation, appointing an authorised representative is not optional and should be completed before market placement begins. By choosing a competent EU Authorized Representative for Medical Devices and IVDs, manufacturers can strengthen compliance, support patient safety and build a reliable foundation for long-term access to the European market.